8-A12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Centessa Pharmaceuticals plc

(Exact name of registrant as specified in its charter)

 

 

 

England and Wales   Not applicable

(State or other jurisdiction of

Incorporation or organization)

 

(I.R.S. Employer

Identification No.)

3rd Floor, 1 Ashley Road

Altrincham, Cheshire, United Kingdom

  WA142DT
(Address of principal executive offices)   (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

 

Name of exchange on which

each class is to be registered

American Depositary Shares, each representing one

ordinary share, nominal value £0.002 per share

  The Nasdaq Stock Market LLC
Ordinary shares, nominal value £0.002 per share*   The Nasdaq Stock Market LLC*

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.  ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.  ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  ☐

Securities Act registration statement file number to which the form relates:

333-255393

Securities to be registered pursuant to Section 12(g) of the Act:

None

(Title of class)

 

*

Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

 

 

 


INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1. Description of Registrant’s Securities to be Registered.

Centessa Pharmaceuticals plc (the “Registrant”) hereby incorporates by reference (a) the description of its ordinary shares, nominal value £0.002 per share, contained under the heading “Description of Share Capital and Articles of Association”, (b) the description of its American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share, contained under the heading “Description of American Depositary Shares” and (c) the information set forth under the heading “Material Income Tax Considerations”, in each case, in the Company’s Registration Statement on Form S-1 (333-255393), as originally filed with the Securities and Exchange Commission on April 21, 2021, as amended from time to time (the “Registration Statement”). In addition, all of the above-referenced descriptions included in any prospectus forming a part of the Registration Statement subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933 shall be deemed to be incorporated by reference herein.

Item 2. Exhibits.

Under the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed with this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.


SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

    CENTESSA PHARMACEUTICALS PLC
Date: May 25, 2021     By:   /s/ Saurabh Saha
      Saurabh Saha, M.D., Ph.D.
      Chief Executive Officer